CD274 and breast carcinoma: Given the significant tumor accumulation of nAlb observed in orthotopic EMT6 breast tumors – and considering that only approximately 20% of breast cancer patients benefit from PD-1/PD-L1 ICB44 – we next evaluated the capacity of nAlb-diABZI to create a TME that inhibited tumor growth.